Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250024/S006

Trilogy Transcatheter Heart Valve System

JenaValve Technology, Inc. · Decision date Oct 7, 2026

MEDTECHLEDGER EXPLANATIONP250024/S006

What did the FDA decide?

The supplied record describes PMA supplement P250024/S006 for the Trilogy Transcatheter Heart Valve System, applicant JenaValve Technology, Inc., with a decision dated 2026-10-07 and a designation shown as OK30. The supplement is a 30-Day Notice under the reason "Process Change - Manufacturer/Sterilizer/Packager/Supplier," and the statement gives its scope as "an alternate supplier for delivery catheter components." The device category is an aortic valve prosthesis delivered percutaneously, product code NPT, specialty Cardiovascular.

The identifier links this supplement to original PMA P250024, so the action amends manufacturing arrangements within that approved filing rather than constituting approval of the whole system. The statement does not identify the alternate supplier, the specific components affected, the prior supplier, or the date any change takes effect; it also does not report safety or clinical effectiveness findings, and the OK30 designation is not explained in the supplied fields.

FDA approval order statement

an alternate supplier for delivery catheter components
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 7, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250024/S006
Regulatory pathway
PMA supplement
Product code
NPT
Decision code
OK30
Decision date
Oct 7, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Aortic valve, prosthesis, percutaneously delivered.

Product code
NPT
FDA device class
3

For the original device and its historical approval scope, see PMA P250024. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250024 · Original PMA

    Trilogy Transcatheter Heart Valve System

  2. P250024/S006 received

    Application receipt date recorded by FDA.

  3. P250024/S006 · FDA decision

    30-Day Notice

  4. P250024/S005 · Related supplement

    Trilogy Transcatheter Heart Valve System

Timeline entries are records held by MedtechLedger for P250024. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250024

Product / regulatory recordCompanyPathwayDecision dateSource
JenaValve Technology, Inc.PMA approvalMar 17, 2026FDA
JenaValve Technology, Inc.PMA supplementOct 13, 2026FDA

Explore the linked device profile

Other records with product code NPT

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

JenaValve Technology, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4 Cromwell, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records